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Abstract
Since the 1980s major advances in surgery, radiotherapy and chemotherapy have established multimodal
approaches as curative treatment options for oesophageal cancer. In addition the introduction of functional
imaging modalities such as PET-CT created new opportunities for a more adequate patient selection and therapy
response assessment.
The majority of oesophageal carcinomas are represented by two histologies: squamous cell carcinoma and
adenocarcinoma. In recent years an epidemiological shift towards the latter was observed. From a surgical point of
view, adenocarcinomas, which are usually located in the distal third of the oesophagus, may be treated with a
transhiatal resection, whereas squamous cell carcinomas, which are typically found in the middle and the upper
third, require a transthoracic approach. Since overall survival after surgery alone is poor, multimodality approaches
have been developed. At least for patients with locally advanced tumors, surgery alone can no longer be
advocated as routine treatment. Nowadays, scientific interest is focused on tumor response to induction
radiochemotherapy. A neoadjuvant approach includes the early and accurate assessment of clinical response,
optimally performed by repeated PET-CT imaging and endoscopic ultrasound, which may permit early adaption of
the therapeutic concept. Patients with SCC that show clinical response by PET CT are considered to have a better
prognosis, regardless of whether surgery will be performed or not. In non-responding patients salvage surgery
improves survival, especially if complete resection is achieved.
1. Surgery
In Western countries, the recent epidemiological shift
from squamous cell carcinoma to adenocarcinoma aris-
ing in Barrett’s metaplasia has led to an increasing refer-
ral of patients with early oesophageal tumours detected
during endoscopic surveillance [1]. Squamous cell carci-
noma (SCC) is associated with low socioeconomic status
[2], active tobacco and alcohol abuse, malnutrition, liver
dysfunction, pulmonary co-morbidities, and second
malignancies [3].
Patients with adenocarcinoma (AC) are characterized
by co-morbidities such as coronary heart disease and a
higher median age [4]. AC is predominantly (94%)
located in the lower third of the oesophagus, whereas
51% of SCC are found in the middle third and only 36%
in the lower third. Moreover, a better prognosis with a
significantly higher overall survival after resection of AC
than SCC was reported in some studies [5-7] whereas a
SEER database review of 4752 patients showed no differ-
ence [8]. However, the majority of patients still present
with advanced disease and up to two thirds are inoper-
able at the time of diagnosis.
Complete resection (R0), N- and T-stage are indepen-
dent prognostic factors for SCC. Patients are categorised
in risk groups by Karnofsky Performance Scale (KPS),
cardiac function, liver and lung parameters [9]. Pre-
operative improvement of nutritional status, abstention
from tobacco and alcohol can decrease the perioperative
risk. Patients with SCC of the cervical oesophagus, T1 -
2, with low surgical risk according to Bartels et al. [9],
can be treated by a limited resection including regional
lymphadenectomy and reconstruction using a free jeju-
nal loop with microsurgical vessel anastomoses, whereas
T3-4 patients are treated with neoadjuvant radioche-
motherapy. Patients with a high perioperative risk get
definitive radiochemotherapy regardless of T-stage. In
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any medium, provided the original work is properly cited.the low risk situation, T1-2 tumours located in the mid-
dle and lower third of the oesophagus are treated with
transthoracic en-bloc-oesophagectomy with two-field
lymphadenectomy and reconstruction with a gastric
tube. Use of the colon as an esophageal substitute is
reserved to patients with previous gastric resection. In
patients with T3-4 tumours the same surgical strategy is
chosen, if possible after preoperative radiochemotherapy.
Again, for patients with higher perioperative risk defini-
tive radiochemotherapy is the treatment of choice. For
AC R0, T- and N-stage are also independent prognostic
markers. Grading is more advantageous in carcinoma of
the gastro-oesophageal junction (GEJ) I than GEJ II/III,
with 80% of intestinal metaplasia (Barrett’so e s o p h a g u s )
being found in GEJ I [6]. The surgical procedure of
choice for GEJ I is subtotal oesophagectomy with proxi-
mal gastric resection and a two-field lymphadenectomy,
whereas GEJ II/III is treated by transhiatal extended gas-
tric resection and oesophagojejunostomy. For early GEJ
I-III a transabdominal limited resection of the distal
oesophagus and the proximal stomach with interposition
of small intestine (Merendino procedure) can be per-
formed. When transthoracic oesophagectomy (TTE) is
compared to the transhiatal oesophagectomy (THE) for
adenocarcinoma of the mid and distal oesophagus, no
significant difference in overall survival can be observed,
but a tendency towards better 5-year survival for TTE
in GEJ I and better locoregional control with limited
lymphnode invasion have been reported [10,11]. Kato et
al. showed a significantly higher overall survival in 3-
field versus 2-field lymphadenectomy [12], whereas a
randomised trial showed no benefit [13]. Cervical lym-
phadenectomy seems to be useful in carcinomas located
in the cervical and upper third of the oesophagus
[13,14]. Transhiatal oesophagectomy is indicated in
patients with high pulmonary risk since it decreases
early morbidity and mortality but has a trend to worse
long term survival. With either a 3-field or a 2-field
approach 5-year overall survival rates of 20% can be
achieved [15]. Hence, oesophagectomy is a complex
operation that entails a two or three-field approach
depending on the site of tumor, clinical staging, and
Karnofsky performance status. Although overall post-
operative mortality has decreased to less than 5% in
high-volume centers [16], anastomotic and respiratory
failures are still frequent [11]. In the past three decades
surgery has developed from transhiatal oesophagectomy
[17] to video-assisted surgery [18,19]. Laparoscopy has
provided the opportunity of minimally invasive surgical
staging [20] and gastric mobilisation with D2 lymphade-
nectomy extended to the lower mediastinal compart-
ment [21,22]. Furthermore, it was shown that hybrid
operations combining laparoscopy and right thoracot-
omy could be advantageous in regards to respiratory
function [23]. A three-stage thoracoscopic oesophagect-
omy with cervical anastomosis may represent a better
minimally invasive surgical option in SCC patients
[24,25]. Expected advantages of minimal access techni-
ques include a decrease in postoperative pain, inflamma-
tory cytokine production, cardiopulmonary
complications, blood loss, and the length of hospital
stay. Although short and medium-term efficacy of these
procedures have been proven [26-28], results are still
inconclusive. As multicentre studies are not available
and because of problems with standardization of such
complex procedures, the effectiveness of minimal access
oesophageal surgery is difficult to demonstrate.
In summary, from a surgical point of view, AC and
SCC need separate therapeutic strategies for which
accurate patient selection (staging, evaluation of co-mor-
bidities) is indispensable. Minimally invasive oesophageal
surgery is evolving and may become increasingly impor-
tant. Still, it is hard to imagine that the management of
oesophageal cancer will merely be based on improved
surgery. Instead, surgeons should be ready for a new
scenario, which comprises biological tumour staging and
targeted therapies combined with neoadjuvant
radiochemotherapy.
2. Radiochemotherapy
For the past three decades combined modality treatment
for cancer of the oesophagus has been investigated in a
number of studies with the intention to improve long-
term outcome. Because of disappointing results of the
intergroup study 0113 [29] perioperative treatment for
oesophageal cancer has been a matter of debate for a
long time. Nowadays we know that the non-stratified
mixture of patients led to a bias. Meanwhile, six meta-
analyses show the value of perioperative radioche-
motherapy [30-35].
2.1 Radiochemotherapy as definitive treatment
One of the first studies analyzing the efficacy of radio-
chemotherapy as definitive treatment was the RTOG
85-01 trial [36,37], which revealed the superiority of
radiochemotherapy compared to radiotherapy alone in
regards to 5-years overall survival. Acute toxicity was
higher in the combined treatment arm, yet no difference
in long term toxicity could be observed. This trial still
exerts a major influence in clinical practice. A meta-ana-
lysis by Wong including 19 (11 concomitant radioche-
motherapy, 8 sequential) trials that compare
radiochemotherapy versus radiotherapy alone concludes
that concomitant radiochemotherapy is better than
sequential radiochemotherapy in regards to overall sur-
vival, disease free survival and local control [38]. The
only study that compared definitive radiochemotherapy
to surgery alone found no statistically significant
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[39] showing, that neither of the two treatment modal-
ities is superior. This study was criticized for ethical
inadequacies (e.g.: no informed consent) and therefore
published only with reserve. Although the intergroup
dose escalation study (INT 123) found no benefit for an
increase from 50.4 to 64.8 Gy, a moderate dose escala-
tion seems useful [40,41].
2.2 Radiochemotherapy in multimodal treatment
approaches
Several studies and three metaanalyses showed a statisti-
cally significant survival benefit for preoperative radio-
chemotherapy plus surgery versus surgery alone
[31,32,35,42,43]. Fiorica found that the effect of preo-
perative radiochemotherapy is even more pronounced in
patients with adenocarcinoma [35]. A metaanalysis
performed by Gebski et al. revealed that both SCC and
adenocarcinoma benefit from preoperative radioche-
motherapy [31]. The problem with some of these trials
is that - by current standards - low to moderate doses
were used because of crude methods of radiation plan-
ning and delivery at the time. Three other metaanalyses
showed no significant survival advantage for preopera-
tive radiochemotherapy [33,34,44]. Due to this inconclu-
siveness we hypothesize that overall survival alone may
be an insufficient parameter to describe the effectiveness
of preoperative radiochemotherapy. In an interesting
study Berger et al. correlate overall survival with com-
plete pathological response (pCR). The 5-year survival
of patients who achieved pCR after preoperative radio-
chemotherapy was almost 50% [45]. The second inde-
pendent predictive marker for overall survival was
complete resection (R0). Thus, the question arises
whether pCR is an integrative biomarker for generally
better prognosis or a pre-requisite for more effective
surgery, in both cases better outcome can be expected.
This is confirmed by two other studies [46,47].
The trials performed by Stahl et al. and Bedenne et al.
showed improved local control with radiochemotherapy
followed by surgery compared to radiochemotherapy
alone. An important result of these studies is that
patients with tumour response to induction chemo
(radio)therapy constitute a favorable prognostic sub-
group. Nevertheless, treatment related mortality in the
surgery arm was 12.8% as opposed to 3.5% with radio-
chemotherapy only [48,49]. These studies suggest that
tumour response to induction radiochemotherapy might
help to identify patients with good prognosis, regardless
of whether surgery will be performed or not. In these
patients surgery can no longer be recommended as rou-
tine treatment [49,50]. But in the group of non-respon-
ders surgery improved survival, especially if complete
resection has been achieved. Future studies are
warranted to increase the number of responders to
induction treatment and to investigate dose escalation
regimens. In these studies the integration of functional
imaging methods for response evaluation is
indispensable.
3. PET/CT for staging and response prediction
Endoscopic ultrasound and computer tomography (CT)
are primarily used for the assessment of local tumour
invasion and locoregional lymph node involvement. For
detection of local lymph node metastases, Positron
emission tomography (PET) with the glucose analogue
2’-[18F]-fluoro-2’-deoxy-D-glucose (FDG) has a limited
sensitivity and specificity of 57% (95% CI, 43%-70%) and
85% (95% CI, 76%-95%), respectively [51]. Therefore, in
the detection of locoregional disease, PET appears to be
inferior to endoscopic ultrasonography. But for the pur-
pose of M-staging FDG-PET is very useful with a sensi-
tivity and specificity of 71% (95% CI, 62%-79%) and 93%
(95% CI, 89%-97%) [51,52], which is crucial for the dif-
ferentiation between locoregional and systemic disease.
In adenocarcinomas of the oesophago-gastric junction
(GEJ), FDG has been established and validated as a sur-
rogate marker for therapy response assessment. A num-
ber of studies showed that FDG-PET allows prediction
of response and prognosis whereas in other studies
FDG-PET was not predictive for response and prognosis
[53]. The MUNICON trial is a unicentre study, which
showed that a PET guided treatment algorithm in
patients with adenocarcinoma of the oesophago-gastric
junction is feasible [54]. The results of this study are
important concerning the individualization of multimo-
dal treatment approaches. The use of FDG PET and
PET/CT for therapy monitoring in oesophageal cancer
is the subject of intense discussion, underlining the need
for randomized multicentre studies.
4. Summary
In summary, the following therapeutic strategies can be
proposed: surgical resection for stage I and IIA, neoad-
juvant chemotherapy (adenocarcinomas) or radioche-
motherapy (squamous cell or adenocarcinomas) plus
surgery for stage IIB. In locally advanced oesophageal
cancer (stage III) - if surgery is potentially possible -
neoadjuvant radiochemotherapy should be followed by
surgery in patients with adenocarcinomas or those
patients with SCC without morphological response after
chemo(radio)therapy. For responders with SCC we con-
sider completion of radiochemotherapy to be the most
appropriate treatment option. Future tasks comprise
improved delivery of radiochemotherapy by integration
of techniques such as IMRT to reduce toxicity, a better
understanding of tumour response by research on mole-
cular profiles to predict pCR and finally clinical
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combined with endoscopic ultrasound [50].
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